Anti-inflammatory drug minimises CV risk in Novartis ’ CANTOS trial

Novartis has reported positive primary results from its Phase III CANTOS clinical trial of ACZ885 (canakinumab) quarterly injections in patients with a history of heart attacks and inflammatory atherosclerosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news